Dartmouth + Innovation + Cancer

Many discoveries now revolutionizing the prevention and treatment of cancer can be traced back to Dartmouth—including immunotherapies for solid tumors, the integration of palliative care with cancer care, and the identification of cancer risks from environmental toxins and behaviors.
Source: News at Dartmouth Medical School - Category: Hospital Management Authors: Tags: Donor Impact Insider News Research campaign cancer Home-feature Interaction Norris Cotton Cancer Center Source Type: news

Related Links:

Conclusions: WBRT remains the cornerstone of the management of brain metastases. The present study concludes that the survival of patients with brain metastases is significantly improved with female gender, good PS, primary breast cancer, time lag of>6 months between diagnosis of the primary tumor and development of brain metastases, solitary lesion, and controlled primary tumor.
Source: Indian Journal of Palliative Care - Category: Palliative Care Authors: Source Type: research
Publication date: May 2018Source: Advances in Biological Regulation, Volume 68Author(s): Aleksandra Adamska, Omar Elaskalani, Aikaterini Emmanouilidi, Minkyoung Kim, Norbaini Binti Abdol Razak, Pat Metharom, Marco FalascaAbstractPancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, em...
Source: Advances in Biological Regulation - Category: Biology Source Type: research
Publication date: June 2018Source: Clinical Plasma Medicine, Volume 10Author(s): Gabriella Pasqual-Melo, Rajesh Kumar Gandhirajan, Ingo Stoffels, Sander BekeschusAbstractMelanoma is the deadliest form of cutaneous neoplasia. With a five-year survival rate of only 5–19%, metastatic melanoma presents severe challenges in clinical therapies. In addition, palliation is often problematic due to large numbers of fast growing metastasis. This calls for new therapeutic avenues targeting highly aggressive melanoma in palliative patients. One recently suggested innovative approach for eradication of topical tumor lesions is th...
Source: Clinical Plasma Medicine - Category: Research Source Type: research
In this study, senescent cell distribution and quantity in vastus lateralis muscle were examined in young human adults after a single bout of resistance exercise. To determine the effects of dietary protein availability around exercise on senescent cell quantity and macrophage infiltration of skeletal muscle, two isocaloric protein supplements (14% and 44% in calorie) were ingested before and immediately after an acute bout of resistance exercise, in a counter-balanced crossover fashion. An additional parallel trial was conducted to compare the outcome of muscle mass increment under the same dietary conditions after 12 wee...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: May 2018Source: Advances in Biological Regulation, Volume 68Author(s): Aleksandra Adamska, Omar Elaskalani, Aikaterini Emmanouilidi, Minkyoung Kim, Norbaini Binti Abdol Razak, Pat Metharom, Marco FalascaAbstractPancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, em...
Source: Advances in Biological Regulation - Category: Biology Source Type: research
Publication date: June 2018Source: Clinical Plasma Medicine, Volume 10Author(s): Gabriella Pasqual-Melo, Rajesh Kumar Gandhirajan, Ingo Stoffels, Sander BekeschusAbstractMelanoma is the deadliest form of cutaneous neoplasia. With a five-year survival rate of only 5–19%, metastatic melanoma presents severe challenges in clinical therapies. In addition, palliation is often problematic due to large numbers of fast growing metastasis. This calls for new therapeutic avenues targeting highly aggressive melanoma in palliative patients. One recently suggested innovative approach for eradication of topical tumor lesions is th...
Source: Clinical Plasma Medicine - Category: Research Source Type: research
This article discusses the indications, treatment considerations, and recommended dose prescriptions for RT in the management of early- and advanced-stage disease. Considerable hope exists that immunotherapy advances will synergize with RT to further enhance clinical outcomes. PMID: 29891527 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
ConclusionsShort-course RT is a compelling strategy that could be a means to augment response in patients with mMCC who show progression on immune checkpoint blockade. Ongoing clinical trials are investigating the relationship between RT and immunotherapy in mMCC.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
hild SI Abstract Head and neck squamous cell carcinoma (HNSCC) is a frequent tumour arising from multiple anatomical subsites in the head and neck region. The treatment for early-stage disease is generally single modality, either surgery or radiotherapy. The treatment for locally advanced tumours is multimodal. For recurrent/metastatic HNSCC palliative chemotherapy is standard of care. The prognosis is limited and novel treatment approaches are urgently needed. HNSCC evades immune responses through multiple resistance mechanisms. HNSCC is particularly characterised by an immunosuppressive environment which include...
Source: Swiss Medical Weekly - Category: General Medicine Authors: Tags: Swiss Med Wkly Source Type: research
We describe a case of pseudoprogression that pushes the limits of immune-related response criteria and challenges the boundaries and definitions set by trial protocols. A middle-aged man with conventional clear cell renal cell carcinoma (RCC) had received multiple prior systemic treatments including vascular endothelial growth factor receptor tyrosine kinase inhibitors, as well as multiple surgeries and radiotherapy treatments. He was eventually started on nivolumab —the anti-programmed death receptor-1 monoclonal antibody approved for the treatment of advanced RCC. Clinical deterioration was observed soon after a 10...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Environmental Health | Hospital Management | Immunotherapy | Palliative | Palliative Care